Peripheral nervous system

Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease

Thursday, September 23, 2021 - 7:00am

Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.

Key Points: 
  • Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.
  • This knowledge is already fueling creation of novel prognostic tests for AD and may lead to the development of new therapies to counter disease progression."
  • p53 is involved in the regulation of oxidative stress, which is implicated as one of the earliest events in AD.
  • Diadem is preparing for rapid commercialization of its initial Alzheimer's prognostic via a global launch in collaboration with strategic partners.

ICBII Announces Approval of Its 7th Patent on Blood-Brain Barrier Permeable Technology, Moving Closer to Clinical Trials on its drugs for Alzheimer's, Parkinson's, and Other Neuro-Degenerative Diseases

Thursday, September 23, 2021 - 1:26am

LA JOLLA, Calif., Sept. 22, 2021 /PRNewswire/ -- Innovative California Biosciences International, Inc., ("ICBII"), has announced the approval of its 7th patent for Blood-Brain Barrier (BBB) Permeable Peptide Compositions.

Key Points: 
  • LA JOLLA, Calif., Sept. 22, 2021 /PRNewswire/ -- Innovative California Biosciences International, Inc., ("ICBII"), has announced the approval of its 7th patent for Blood-Brain Barrier (BBB) Permeable Peptide Compositions.
  • Approval of this patent further strengthens Company's IP portfolio of its SMART* Molecules technology and brings the management closer to the clinical trials.
  • ICBII's SMART molecules technology is blazing the path to non-invasively diagnosis and potentially curing brain diseases by delivering drugs to targeted sites that has not been possible so far.
  • The drugs that do cross the blood brain barrier only provide short-term symptomatic relief without altering disease progression.

Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science

Wednesday, September 22, 2021 - 9:05pm

Renovacor, Inc. (NYSE: RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science.

Key Points: 
  • Renovacor, Inc. (NYSE: RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science.
  • We are excited to welcome Jordan to Renovacors leadership team during this pivotal time for the company, said Magdalene Cook, M.D., Chief Executive Officer of Renovacor.
  • Dr. Shin added, Its an honor to join Renovacors team of highly motivated and experienced industry experts.
  • Prior to joining Renovacor, Dr. Shin served as Vice President of Medical Development at Lung Biotechnology, PBC, a subsidiary of United Therapeutics, Inc.

Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand

Wednesday, September 22, 2021 - 12:00pm

The meeting will offer both in-person and online attendance options with live-streaming of select sessions and on-demand access to pre-recorded scientific presentations.

Key Points: 
  • The meeting will offer both in-person and online attendance options with live-streaming of select sessions and on-demand access to pre-recorded scientific presentations.
  • Attending surgeons will have the opportunity to chat live with Axogen scientists, clinicians, and other experts at Booth #950 in the Solutions Center (exhibit hall).
  • The annual ASSH meeting provides a unique and invaluable opportunity for us to connect with surgeons and share our innovative surgical solutions for nerve repair.
  • The American Society for Surgery of the Hand is the oldest medical society dedicated to the hand and upper extremity.

Jupiter Neurosciences, Inc. Announces New Corporate Offices

Tuesday, September 21, 2021 - 1:49pm

Additionally, Jupiter has established an office at 127 Main Street, Boston, MA 02129.

Key Points: 
  • Additionally, Jupiter has established an office at 127 Main Street, Boston, MA 02129.
  • "We expect to announce exciting additions to our management team as well, so stay tuned for more news."
  • Jupiter Neurosciences has developed a unique and patented platform product, JOTROL, an enhancedresveratrol formulationthatdeliverssuperior oral bioavailability with a strong safety profile.
  • Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on treating CNS disorders and rare diseases.

AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology

Monday, September 20, 2021 - 6:15pm

This abstract has received the honor of being designated as an extended comunicacin oral estelar (stellar oral communication).

Key Points: 
  • This abstract has received the honor of being designated as an extended comunicacin oral estelar (stellar oral communication).
  • We first suspected that masitinib may generate improved survival in certain subgroups through observation of patients enrolled in study AB10015 at the Vall d'Hebron Hospital's ALS Unit [2].
  • 2020;21(1-2):5-14. doi:10.1080/21678421.2019.1632346
    [2] Gamez J. Vall dHebron participates in an international study to validate masitinib for amyotrophic lateral sclerosis treatment.
  • In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy.

Forge Biologics Announces Regulatory Updates from FDA and EMA, Accelerating Manufacturing and Clinical Trial Momentum

Monday, September 20, 2021 - 1:00pm

FBX-101 previously received Orphan Drug and Rare Pediatric Disease Designations from the FDA earlier this year.

Key Points: 
  • FBX-101 previously received Orphan Drug and Rare Pediatric Disease Designations from the FDA earlier this year.
  • Forge presented information to the FDA on its proprietary HEK293 suspension cell line, Ignition Cells, and adenovirus helper plasmid, pEMBR, and received FDA alignment that these technologies are suitable for cGMP manufacturing of clinical drug products.
  • The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.
  • By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

Lyndra Therapeutics Advances Leadership in Key Roles

Monday, September 20, 2021 - 1:30pm

Ballinger has been a member of the Lyndra leadership team since 2016, and has played a leading role in building Lyndra as Chief Operations Officer and, previously, Vice President of Reimbursement and Strategic Alliances.

Key Points: 
  • Ballinger has been a member of the Lyndra leadership team since 2016, and has played a leading role in building Lyndra as Chief Operations Officer and, previously, Vice President of Reimbursement and Strategic Alliances.
  • Jess is a builder, said Dr. Patricia Hurter, Chief Executive Officer of Lyndra Therapeutics.
  • Over the past five years, she has been a key partner in getting Lyndra to where it is today: on the cusp of our first pivotal trial and building toward commercialization.
  • Thats the kind of leadership we value at Lyndra, and Im thrilled to continue to partner with her as we move Lyndra forward.

AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)

Thursday, September 16, 2021 - 6:34pm

Authorizations to resume patient enrollment have already been received from European and National agencies [1] [2] for the confirmatory Phase 3 study (AB19001) in amyotrophic lateral sclerosis and the confirmatory Phase 3 study (AB15003) in mastocytosis.

Key Points: 
  • Authorizations to resume patient enrollment have already been received from European and National agencies [1] [2] for the confirmatory Phase 3 study (AB19001) in amyotrophic lateral sclerosis and the confirmatory Phase 3 study (AB15003) in mastocytosis.
  • The combination of masitinib and isoquercetin may prevent the development of these two complications.
  • The Data and Safety Monitoring Board(DSMB) have met twice since the beginning of the study and have recommended continuation of the study on both occasions.
  • AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq.

Newron Announces Half-Year 2021 Results

Thursday, September 16, 2021 - 12:00pm

Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights and financial results for the half-year ended June 30, 2021.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights and financial results for the half-year ended June 30, 2021.
  • In April, Newron announced encouraging results from two short-term explanatory studies in evenamide: study 010 in 56 healthy volunteers, and study 008 in 138 outpatients with chronic schizophrenia, receiving treatment with a second-generation atypical antipsychotic.
  • Based on this encouraging data and supported by the pre-clinical results published last year confirming the absence of toxicity, Newron, on September 6, 2021, initiated study 008A, the first potentially pivotal study with evenamide in patients with chronic schizophrenia.
  • Newron believes that positive results from this study would qualify the trial as the first adequate and well-controlled (pivotal) study with evenamide in patients with schizophrenia who are inadequate responders to antipsychotics.